RE:3 quick points...RG... I respect your opinion but I wouldn't get overly caught up in the continued misspelling of McRae.
Also, I am not surprised that GW shows little interest in Urocidin publicly. There is no reason to validate the company's efforts here. The product most likely will be a success in their hands, but has little to know chance under current management, as the complete lack of interest in a partnership would indicate.
the meeting July 9th is probably little more than the standard McRae plead for more time and the positioning of blame on anyone but him and those that report to him. He might as well blame the short people of Borneo for all the weight it carries.
finally, did you read the setting the record straight section of the new sight? I am convinced that one of the reasons we were never to hear of an overture from GW is the clear suggestion that anything they proposed involved the removal of McRae from the CEO and Board. He was going to be let go under their leadership and that offer could have been a billion, ten billion, but with that clause it was never to see the light of day and absolutely never brought to a shareholder vote.
That is your current leadership and our current BOD looking out for our best interests.